Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?

Alison F Munro, Annette Bartels, Eva Balslev, Christopher J Twelves, David A Cameron, Nils Brünner, John Ms Bartlett

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science